Clearside Biomedical, which is developing drugs and proprietary microinjector to combat diseases causing blindness, filed on Friday with the SEC to raise up to $58 million in an initial public offering.
The Alpharetta, GA-based company, which was founded in 2011, plans to list on the Nasdaq under the symbol CLSD. Clearside Biomedical filed confidentially on 6/24/2014. RBC Capital Markets and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
